Results 221 to 230 of about 1,546,421 (373)
Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?
Molecular Oncology, EarlyView.Chen‐xi Li, Zhong‐cheng Gong
wiley +1 more source
Author's Reply to Gonçalves: "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review". [PDF]
BioDrugsLee CS.
europepmc +1 more source
Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence
Molecular Oncology, EarlyView.The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova +18 more
wiley +1 more source
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors. [PDF]
JCO Precis OncolO'Sullivan Coyne G +19 more
europepmc +1 more source
Molecular Oncology, EarlyView.Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma +9 more
wiley +1 more source
A plain language summary of two trials for larotrectinib in people with TRK fusion-positive lung cancer to learn how well the drug works and how safe it is. [PDF]
Future OncolDrilon A +6 more
europepmc +1 more source
A Text-Book of Pharmacology, Therapeutics and Materia Medica. [PDF]
, 1886 T. Lauder Brunton, FRANCIS H. WILLIAMS
openalex +1 more source